Troubled Dendreon gets EC OK for Provenge; Acacia launches pivotal studies;

@FierceBiotech: ICYMI yesterday: CDC director warns antibiotics pipeline 'nearly empty.' Story | Follow @FierceBiotech

@JohnCFierce: Regado CEO moves the goal line after a rare biotech IPO misfire. More | Follow @JohnCFierce

> Dendreon shares ($DNDN) jumped about 10% this morning after the biotech reported that the European Commission had approved Provenge, its struggling prostate cancer therapy, which has experienced profound trouble in developing a market in the U.S. Story

> The U.K.'s Acacia Pharma launched two pivotal Phase III studies of APD421 in the prevention of post-operative nausea and vomiting. Release

> The European Commission has also approved Sanofi's ($SNY) MS drug Lemtrada, which was developed by Genzyme. Story

Medical Device News

@FierceMedDev: Special Report: 'Big' med tech M&A deals getting smaller. Feature | Follow @FierceMedDev

@DamianFierce: VisionCare landed up to $15M to market its AMD-treating eye implant. News | Follow @DamianFierce

@MarkHFierce: The U.S. will now have the first permanent implant designed to treat enlarged prostates. Expect a gradual launch. ICYMI yesterday | Follow @MarkHFierce

@MichaelGFierce: Abbott snags CE mark for diabetes monitor. Item | Follow @MichaelGFierce

> Europe risks more delays on device reg reform. More

> Medtronic cuts ribbon on $10M Irish R&D shop. Story

> Boston Scientific debuts teaching, R&D centers in China. Article

Pharma News

@FiercePharma: Now armed with EU nod for Lemtrada, Sanofi preps to launch its multiple sclerosis duo (with Aubagio). Release (PDF) | Follow @FiercePharma

@CarlyHFierce: Whistleblower codenamed Zorro implicates Novartis' Alcon division in Chinese bribery scandal. More from The Financial Times Follow @CarlyHFierce

> Novartis faces second set of bribery claims in China. More

> FDA approves Teva's generic of Roche blockbuster Xeloda. Article

Pharma Manufacturing News

@EricPFierce: Now that Ranbaxy's Mohali plant falls under FDA consent decree, oversight ramps up significantly. Article | Follow @EricPFierce

> Cargill invests $15M in French alginate plant. Item

> Hospira recalls bupivacaine because of steel particles in vials. Story

> Strides gets FDA warning for plant Mylan is buying. More

> J&J sues Ben Venue over Doxil shortage. Report

Biotech Research News

@EmilyMFierce: Initial focus of BRAIN Initiative laid out, but are the goals any clearer than they were in April? Check out the story and weigh in | Follow @EmilyMFierce

> Visterra antibody shows promise in preclinical study as universal flu vaccine. Item

> NIH partners with Eli Lilly, others on rare diseases. Article

> Experimental vaccine clears monkeys of HIV-like virus. More

> Genia Technologies, Columbia, Harvard nab $5.3M NIH grant for genome sequencing. Story

And Finally... No, this isn't an image of a far-away galaxy. It's a map of 873,344 scientific papers across various disciplines. 

Suggested Articles

When thinking about clinical research patient recruitment, a crucial step is building effective patient recruitment advertising campaigns.

Novavax delayed the start of a large phase 3 trial for its COVID-19 vaccine in the U.S. and Mexico, thanks to delays in scaling up manufacturing.

The decision to dump IL33r antagonist GSK3772847 follows lackluster clinical data on rival candidates against the same target.